FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis
FDA approved Papzimeos, the first-of-its-kind non-replicating adenoviral vector-based immunotherapy for use in adults with recurrent respiratory papillomatosis.
FDA approved Papzimeos, the first-of-its-kind non-replicating adenoviral vector-based immunotherapy for use in adults with recurrent respiratory papillomatosis.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.